Stocks · News reference
Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and raises the price target from $40 to $70.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
10x Genomics, Inc. announced that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 17, 2026.
Stephens has downgraded 10x Genomics, Inc. from Overweight to Equal Weight, setting a price target of $65.
The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs.
TD Cowen analyst Dan Brennan maintains 10x Genomics (NASDAQ:TXG) with a Hold and raises the price target from $47 to $70.